|
시장보고서
상품코드
2117739
올란자핀(CAS 132539-06-1) 시장 규모, 점유율, 성장 분석 : 제형별, 적응증별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Olanzapine CAS 132539-06-1 Market Size, Share, and Growth Analysis, By Dosage Form (Tablets, Orally Disintegrating Tablets), By Indication (Schizophrenia, Bipolar Disorder), By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 올란자핀(CAS 132539-06-1) 시장 규모는 2024년에 2억 1,470만 달러로 평가되며, 2025년 2억 2,780만 달러에서 2033년까지 3억 6,582만 달러로 확대될 전망이며, 예측 기간(2026-2033년) 동안 연평균 성장률(CAGR) 6.1%로 성장할 것으로 전망됩니다..
CAS 132539-06-1과 관련된 전 세계 올란자핀 시장은 주로 조현병 및 양극성 장애 치료를 목적으로 하는 2세대 항정신병 약물을 중심으로 구성되어 있습니다. 이 약물은 피라미드 외계 부위의 부작용을 최소화하면서 정신병적 증상을 완화하는 효과가 높이 평가되어 다양한 의료 현장에서 널리 사용되고 있습니다. 신흥국에서의 접근성 확대에 힘입어 시장은 현저한 성장을 이루고 있으며, 이는 수요를 확대하고 공급망을 다각화하는 각국의 의료 정책에 의해 뒷받침되고 있습니다. 주목할 만한 동향으로는 정신 질환 유병률의 상승과 더불어 항정신병 약물에 대한 보험 적용 범위 확대가 꼽히며, 이에 따라 유지 요법을 위한 처방전이 증가하고 있습니다. 이러한 상황에 따라 각 제약사는 장시간 작용형 제제 개발에 주력하고, 파트너십 구축을 추진하는 등 혁신에 힘쓰고 있으며, 그 결과 시장의 회복력이 강화되고 새로운 수익 기회가 열리고 있습니다.
세계 올란자핀(CAS 132539-06-1) 시장의 성장요인
다양한 인구 집단에서 조현병 유병률이 증가함에 따라 항정신병약 수요가 크게 증가하고 있으며, 그 효능이 입증된 올란자핀은 주요 치료 옵션으로서의 입지를 확고히 하고 있습니다. 의료 종사자들의 인식 제고와 진단율 상승이 맞물려 지속적인 관리가 필요한 환자층이 확대되고 있습니다. 이러한 추세로 인해 처방률이 급증하면서, 제조사들은 생산을 확대하고 시장 성장을 위한 노력에 투자하도록 유도되어 시장을 더욱 견인하고 있습니다. 또한, 보험 적용 범위 확대와 유리한 환급 정책으로 인해 환자의 접근성이 향상되고 있으며, 이는 안정적인 처방 추세를 강화하여 올란자핀의 세계 성장에 기여하고 있습니다.
세계 올란자핀(CAS 132539-06-1) 시장의 제약요인
세계 올란자핀 시장은 안전성과 유효성에 관한 종합적인 임상 데이터를 요구하는 엄격한 규제 요건으로 인해 중대한 제약에 직면해 있습니다. 이러한 요건으로 인해 제조사들은 막대한 시간과 자원을 투입할 수밖에 없으며, 이는 제품 개발 일정에 큰 영향을 미치고 있습니다. 또한, 규제 당국은 표시, 시판 후 조사 및 제조 관행에 대해 엄격한 지침을 부과하고 있으며, 이는 제품 출시를 방해하고 개발 비용을 증가시킬 가능성이 있습니다. 규정 준수 의무의 강화는 치료 솔루션에 대한 수요가 지속되고 있음에도 불구하고 신규 진입자의 의지를 꺾고 시장 전체의 성장을 둔화시킬 가능성이 있습니다. 이러한 엄중한 상황은 경쟁 압력을 강화하여 시장 확대의 모멘텀을 더욱 저해하게 될 것입니다.
세계 올란자핀(CAS 132539-06-1) 시장 동향
세계 올란자핀 시장에서는 정밀 정신의학으로의 뚜렷한 전환이 나타나고 있으며, 유전자, 대사 및 증상 특이적 데이터를 활용한 개별화된 용량과 제제를 중시하는, 환자 한 명 한 명에게 맞춘 치료 접근법이 강조되고 있습니다. 이러한 동향에 따라 고순도 의약품 유효 성분(API)에 대한 수요가 증가하고 있으며, 제약사와 진단 기술 혁신 기업 간의 협력이 촉진되고 있습니다. 의료 서비스 제공자들이 예측 가능한 치료 결과를 중시함에 따라, 제조업체들은 로트 간 일관된 품질 확보, 첨단 제형 기술의 도입, 그리고 맞춤형 치료 전략에 부합하는 임상 지원 프로그램 강화에 점점 더 주력하고 있습니다. 이러한 진화는 다양한 세계 시장에서 현대 정신의학 치료에 있어 올란자핀의 중요성을 더욱 공고히 하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 올란자핀(CAS 132539-06-1) 시장 규모 : 제형별
세계의 올란자핀(CAS 132539-06-1) 시장 규모 : 적응증별
세계의 올란자핀(CAS 132539-06-1) 시장 규모 : 유통 채널별
세계의 올란자핀(CAS 132539-06-1) 시장 규모 : 최종사용자별
세계의 올란자핀(CAS 132539-06-1) 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.27Global Olanzapine Cas 132539-06-1 Market size was valued at USD 214.7 Million in 2024 and is poised to grow from USD 227.8 Million in 2025 to USD 365.82 Million by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).
The global olanzapine market, linked to CAS 132539-06-1, is centered on second-generation antipsychotics, primarily targeting schizophrenia and bipolar disorder treatment. This drug is valued for its effectiveness in mitigating psychotic episodes with fewer extrapyramidal side effects, leading to its extensive use in various healthcare settings. The market has witnessed significant growth due to increasing access in emerging economies, supported by national health initiatives that enhance demand and diversify the supply chain. A notable trend is the rising prevalence of mental health conditions, coupled with expanded insurance coverage for antipsychotics, leading to increased prescriptions for maintenance therapy. This has prompted manufacturers to innovate, focusing on long-acting formulations and fostering partnerships, thus strengthening market resilience and unlocking new revenue opportunities.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Olanzapine Cas 132539-06-1 market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Olanzapine Cas 132539-06-1 Market Segments Analysis
Global olanzapine cas 132539-06-1 market is segmented by dosage form, indication, distribution channel, end user and region. Based on dosage form, the market is segmented into tablets, orally disintegrating tablets and injectable. Based on indication, the market is segmented into schizophrenia, bipolar disorder and treatment-resistant depression. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, psychiatric clinics and home care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Olanzapine Cas 132539-06-1 Market
The increasing prevalence of schizophrenia among various populations significantly fuels the demand for antipsychotic medications, positioning olanzapine as a primary treatment option due to its proven effectiveness. Enhanced awareness among healthcare providers, paired with rising rates of diagnosis, results in a larger patient demographic requiring sustained management. This trend leads to an upsurge in prescribing rates, prompting manufacturers to ramp up production and invest in market growth initiatives, further propelling the market forward. Additionally, improved insurance coverage and favorable reimbursement policies enhance accessibility for patients, thereby reinforcing steady prescribing trends and contributing to the global growth of olanzapine.
Restraints in the Global Olanzapine Cas 132539-06-1 Market
The global Olanzapine market faces significant constraints stemming from stringent regulatory requirements that necessitate comprehensive clinical data on safety and efficacy. These demands require manufacturers to invest considerable time and resources, significantly impacting product development timelines. Additionally, regulatory bodies impose strict guidelines on labeling, post-marketing monitoring, and manufacturing practices, which can hinder product launches and escalate development expenses. The heightened compliance obligations can discourage new market entrants and slow overall market growth despite an ongoing demand for therapeutic solutions. This challenging landscape intensifies competitive pressures, further impeding the dynamics of market expansion.
Market Trends of the Global Olanzapine Cas 132539-06-1 Market
The Global Olanzapine market is experiencing a notable shift toward precision psychiatry, emphasizing tailored treatment approaches that utilize genetic, metabolic, and symptom-specific data for personalized dosing and formulations. This trend is elevating the demand for higher-purity active pharmaceutical ingredients (APIs) and fostering collaborations between pharmaceutical companies and diagnostic innovators. As healthcare providers prioritize predictable therapeutic outcomes, manufacturers are increasingly focused on ensuring consistent batch quality, employing advanced formulation technologies, and enhancing clinical support programs that align with individualized treatment strategies. This evolution reinforces olanzapine's significance in contemporary psychiatric care across diverse global markets.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Olanzapine CAS 132539-06-1 Market Size by Dosage Form & CAGR (2026-2033)
- Market Overview
- Tablets
- Orally Disintegrating Tablets
- Injectable
Global Olanzapine CAS 132539-06-1 Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Schizophrenia
- Bipolar Disorder
- Treatment-Resistant Depression
Global Olanzapine CAS 132539-06-1 Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Olanzapine CAS 132539-06-1 Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Psychiatric Clinics
- Home Care
Global Olanzapine CAS 132539-06-1 Market Size & CAGR (2026-2033)
- North America (Dosage Form, Indication, Distribution Channel, End User)
- US
- Canada
- Europe (Dosage Form, Indication, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Dosage Form, Indication, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Dosage Form, Indication, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Dosage Form, Indication, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alkem Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hetero Labs Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Apotex Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz Group AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amneal Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alembic Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Glenmark Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MSN Laboratories Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Farmak JSC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
(주말 및 공휴일 제외)
